Takeda Pharmaceutical Co ( (TKPHF) ) has released its Q1 earnings. Here is a breakdown of the information Takeda Pharmaceutical Co presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Takeda Pharmaceutical Company Limited is a global pharmaceutical company based in Japan, specializing in research and development of innovative medicines across various therapeutic areas including oncology, gastroenterology, and neuroscience. It is listed on multiple stock exchanges including Tokyo and Nagoya.
In its latest earnings report for the three-month period ending June 30, 2025, Takeda Pharmaceutical reported a decrease in revenue by 8.4% compared to the same period last year, primarily due to unfavorable foreign exchange rates and a decline in its neuroscience segment. However, the company achieved a notable increase in net profit by 30.4% year-on-year, driven by improved operating profit and reduced income tax expenses.
Key financial highlights include a revenue of JPY 1,106.7 billion, an operating profit of JPY 184.6 billion, and a net profit of JPY 124.3 billion. Despite the revenue decline, the operating profit increased by 11%, reflecting effective cost management and gains from divestments. The company’s core operating profit and core EPS also saw declines, attributed to currency impacts and competitive pressures in certain markets.
Looking ahead, Takeda maintains its full-year forecast for fiscal year ending March 31, 2026, with expectations of broadly flat growth in core revenue, operating profit, and EPS on a constant exchange rate basis. The management remains focused on strategic growth areas and optimizing its product portfolio to navigate the challenging market conditions.